Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

March 8, 2022 by Alan Khadavi

Itepekimab in Asthma and COPD

Itepekimab is an anti-Il-33 monoclonal. Il-33 is an epithelium-derived cytokine that promotes Th2 immune responses in response to cellular damage with roles in asthma and COPD (Chronic Obstructive Pulmonary Disease).

Two randomized controlled clinical trials were performed assessing the efficacy of Itepekimab in asthma and COPD.

After identifying the asthma associated variants in the genes encoding IL-33 or its receptor IL1RL1, also modifying the risk of COPD, the investigators performed a phase 2 placebo-controlled trial in patients with moderate to severe COPD. This study published in the Lancet. Itepekimab did not reduce the annualized rate of exacerbations overall but did so in a prespecified subgroup of former smokers.

Published in The New England Journal of Medicine, investigators performed a phase 2 placebo controlled trial assessing itepekimab in combination with dupilumab, which inhibits the downstream signaling pathways of both Il-4 and IL-13, in patients with moderate to severe asthma. The combination of of itepekimab and dupilumab reduced the incidence of loss of asthma control and improved lung function, but were not superior to each drug alone.

These studies highlight the potential of targeting IL-33 in COPD and asthma.

The last several years many new biological drugs have been released for asthma. Targeted therapy is being used for particular patients. In the past for asthma, it was just a “one sized fits all” approach for asthma, all patient were usually given a steroid inhaler as first line approach. But over the years, different subtypes of asthma have been discovered. For patients with allergic asthma, Xolair is given for patients who have an elevated IgE.

For patients with eosinophilic asthma, there are 3 medications currently available, Nucala, Fasenra and Cinqair.

For patients with steroid dependent asthma and eosinophilic asthma, Dupixent is another biologic. And for patients with “other” types of asthma, Tezspire can be used.

Itepekimab may be a choice in the future for patients who have associated issues with IL-33 or its receptor. Currently there is no commercial testing to check patients who have abnormalities with those biomarkers, but it could be potentially be tested and used in the future.

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 22, 2023

Is Benadryl Safe to use, or is it Time to Move on?

is benadryl safe

January 12, 2023

Airsupra for Asthma, a new rescue medication

airsupra

December 26, 2022

Cantaloupe Allergy comes in many flavors

cantaloupe allergy

December 23, 2022

Remibrutinib, a BTK inhibitor for Chronic Hives

remibrutininb

November 21, 2022

Eczema and Hard Water, is there a link?

eczema and hard water

November 19, 2022

Nucala, Fasenra or Dupixent for Severe Eosinophilic Asthma?

nucala fasenra dupixent

November 18, 2022

Xolair for idiopathic angioedema

xolair for idiopathic angioedema

September 29, 2022

When will my child outgrow egg allergy?

outgrow egg allergy

September 13, 2022

Can you be allergic to water? (Aquagenic Urticaria)

allergic to water

September 8, 2022

Oclacitinib for Atopic Dermatitis (Eczema) in Dogs

oclacitinib

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page